Objective to investigate the expression of neurokinin-3 receptor (NK-3R) in pancreatic cancer and evaluate the relationship between expression of this receptor and clinical aspect.
The present invention is directed to certain lactam compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance p.
The present invention is directed to certain quinoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance p.